Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yamagishi S is active.

Publication


Featured researches published by Yamagishi S.


Journal of Biological Chemistry | 2002

Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells.

Yamagishi S; Yosuke Inagaki; Tamami Okamoto; Shinjiro Amano; Kohachiro Koga; Masayoshi Takeuchi; Zenji Makita

Advanced glycation end products (AGE) have been implicated in the pathogenesis of glomerulosclerosis in diabetes. However, their involvement in the development of the early phase of diabetic nephropathy has not been fully elucidated. We investigated the effects of AGE on growth and on vascular endothelial growth factor (VEGF) and monocyte chemoattractant protein-1 (MCP-1) expression in human cultured mesangial cells. We prepared three immunochemically distinct AGE by incubating bovine serum albumin (BSA) with glucose, glyceraldehyde, or glycolaldehyde. When human mesangial cells were cultured with various types of AGE-BSA, viable cell numbers as well as DNA syntheses were significantly decreased. All of the AGE-BSA were found to significantly increase p53 and Bax protein accumulations and subsequently induce apoptotic cell death in mesangial cells. An antioxidant, N-acetylcysteine, significantly prevented the AGE-induced apoptotic cell death in mesangial cells. Human mesangial cells stimulated prostacyclin production by co-cultured glomerular endothelial cells. Furthermore, various types of AGE-BSA were found to up-regulate the levels of mRNAs for VEGF and stimulate the secretion of VEGF and MCP-1 proteins in mesangial cells. The results suggest that AGE disturbed glomerular homeostasis by inducing apoptotic cell death in mesangial cells and elicited hyperfiltration and microalbuminuria by stimulating the secretion of VEGF and MCP-1 proteins, thereby being involved in the pathogenesis of the early phase of diabetic nephropathy.


Kidney International | 2003

Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells

Yamagishi S; Yosuke Inagaki; Tamami Okamoto; Shinjiro Amano; Kohachiro Koga; Masayoshi Takeuchi


International Journal of Clinical Pharmacology Research | 2003

Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.

Yamagishi S; Masayoshi Takeuchi; Yosuke Inagaki; Kei-ichiro Nakamura; T. Imaizumi


Drugs Under Experimental and Clinical Research | 2004

Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation

Yamagishi S; Masayoshi Takeuchi


International Journal of Clinical Pharmacology Research | 2002

Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction.

Kohachiro Koga; Yamagishi S; Tamami Okamoto; Yosuke Inagaki; Shinjiro Amano; Masayoshi Takeuchi; Zenji Makita


International Journal of Tissue Reactions-experimental and Clinical Aspects | 2002

Up-regulation of vascular endothelial growth factor and down-regulation of pigment epithelium-derived factor messenger ribonucleic acid levels in leptin-exposed cultured retinal pericytes.

Yamagishi S; Yosuke Inagaki; Shinjiro Amano; Tamami Okamoto; Masayoshi Takeuchi


Drugs Under Experimental and Clinical Research | 2003

Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation.

Yamagishi S; Yosuke Inagaki; Seiji Kikuchi


International Journal of Tissue Reactions-experimental and Clinical Aspects | 2005

Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.

Yamagishi S; Takanori Matsui; Kei-ichiro Nakamura; Masayoshi Takeuchi


International Journal of Clinical Pharmacology Research | 2004

Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention

Yamagishi S; Kei-ichiro Nakamura; Masayoshi Takeuchi; T. Imaizumi


International Journal of Tissue Reactions-experimental and Clinical Aspects | 2003

Angiotensin II stimulates platelet-derived growth factor-B gene expression in cultured retinal pericytes through intracellular reactive oxygen species generation.

Shinjiro Amano; Yamagishi S; Yosuke Inagaki; Tamami Okamoto

Collaboration


Dive into the Yamagishi S's collaboration.

Top Co-Authors

Avatar

Masayoshi Takeuchi

Kanazawa Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge